Literature DB >> 2015713

Tumour necrosis factor-alpha synthesis by cerebrospinal-fluid-derived T cell clones from patients with multiple sclerosis.

R Benvenuto1, M Paroli, C Buttinelli, A Franco, V Barnaba, C Fieschi, F Balsano.   

Abstract

T cell clones derived from cerebrospinal fluid (CSF) of patients with multiple sclerosis (MS) were analysed for their ability to produce interferon-gamma (IFN-gamma), tumour necrosis factor-alpha (TNF-alpha), interleukin-2 (IL-2) and interleukin-4 (IL-4). The CSF-T clones were compared for their ability to produce cytokines with autologous peripheral T clones and with liver-infiltrating T cell clones from patients with chronic active hepatitis. IL-4 production was also compared with that by peripheral T clones derived from atopic patients. All the CSF-T clones (both CD4+ and CD8+) produced large amounts of IFN-gamma and particularly of TNF-alpha. These cytokines were synthesized in significantly larger amounts by CSF T clones than by reference clones. Moreover, they were capable of secreting IL-2, but not IL-4. We conclude that the CSF-CD4+ T clones could constitute a subset with functional properties similar to those of T helper 1 (Th1)inflammatory cells of the mouse; and that the large amounts of TNF produced by CSF T cell clones strongly suggest a significant role for this cytokine in MS immunopathogenesis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2015713      PMCID: PMC1535361     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  48 in total

1.  PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS.

Authors:  G A SCHUMACHER; G BEEBE; R F KIBLER; L T KURLAND; J F KURTZKE; F MCDOWELL; B NAGLER; W A SIBLEY; W W TOURTELLOTTE; T L WILLMON
Journal:  Ann N Y Acad Sci       Date:  1965-03-31       Impact factor: 5.691

2.  Astrocytes present myelin basic protein to encephalitogenic T-cell lines.

Authors:  A Fontana; W Fierz; H Wekerle
Journal:  Nature       Date:  1984 Jan 19-25       Impact factor: 49.962

3.  In vivo activated T lymphocytes in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis.

Authors:  D A Hafler; D A Fox; M E Manning; S F Schlossman; E L Reinherz; H L Weiner
Journal:  N Engl J Med       Date:  1985-05-30       Impact factor: 91.245

4.  Suppressor cell function in multiple sclerosis: correlation with clinical disease activity.

Authors:  J P Antel; B G Arnason; M E Medof
Journal:  Ann Neurol       Date:  1979-04       Impact factor: 10.422

5.  Inducible expression of H-2 and Ia antigens on brain cells.

Authors:  G H Wong; P F Bartlett; I Clark-Lewis; F Battye; J W Schrader
Journal:  Nature       Date:  1984 Aug 23-29       Impact factor: 49.962

6.  Phenotypic and functional analysis of T cells cloned directly from the blood and cerebrospinal fluid of patients with multiple sclerosis.

Authors:  D A Hafler; M Buchsbaum; D Johnson; H L Weiner
Journal:  Ann Neurol       Date:  1985-10       Impact factor: 10.422

7.  Decreased autologous mixed lymphocyte reaction in multiple sclerosis.

Authors:  D A Hafler; M Buchsbaum; H L Weiner
Journal:  J Neuroimmunol       Date:  1985-10       Impact factor: 3.478

8.  Multiple sclerosis and human T-cell lymphotropic retroviruses.

Authors:  H Koprowski; E C DeFreitas; M E Harper; M Sandberg-Wollheim; W A Sheremata; M Robert-Guroff; C W Saxinger; M B Feinberg; F Wong-Staal; R C Gallo
Journal:  Nature       Date:  1985 Nov 14-20       Impact factor: 49.962

9.  Phenotypic markers and functional characteristics of T lymphocyte clones from cerebrospinal fluid in multiple sclerosis.

Authors:  B Fleischer; P Marquardt; S Poser; H W Kreth
Journal:  J Neuroimmunol       Date:  1984-12       Impact factor: 3.478

10.  Temporal invariance and clonal uniformity of brain and cerebrospinal IgG, IgA, and IgM in multiple sclerosis.

Authors:  M J Walsh; W W Tourtellotte
Journal:  J Exp Med       Date:  1986-01-01       Impact factor: 14.307

View more
  7 in total

1.  Patterns of disease activity in multiple sclerosis patients: a study with quantitative gadolinium-enhanced brain MRI and cytokine measurement in different clinical subgroups.

Authors:  M Rovaris; D Barnes; N Woodrofe; G H du Boulay; J W Thorpe; A J Thompson; W I McDonald; D H Miller
Journal:  J Neurol       Date:  1996-07       Impact factor: 4.849

Review 2.  Mechanisms of action of interferon-beta in multiple sclerosis.

Authors:  B G Arnason; A Dayal; Z X Qu; M A Jensen; K Genç; A T Reder
Journal:  Springer Semin Immunopathol       Date:  1996

Review 3.  Multiple sclerosis: a unique immunopathological syndrome of the central nervous system.

Authors:  S F Hunter; M Rodriguez
Journal:  Springer Semin Immunopathol       Date:  1995

4.  A new approach for evaluating antigen-specific T cell responses to myelin antigens during the course of multiple sclerosis.

Authors:  Nathalie Arbour; Andreas Holz; Jack C Sipe; Denise Naniche; John S Romine; Jack Zyroff; Michael B A Oldstone
Journal:  J Neuroimmunol       Date:  2003-04       Impact factor: 3.478

5.  Glucocorticoid receptors are downregulated in hepatic T lymphocytes in rats with experimental cholangitis.

Authors:  K Tjandra; T Le; M G Swain
Journal:  Gut       Date:  2003-09       Impact factor: 23.059

6.  Genetic, Immune-Inflammatory, and Oxidative Stress Biomarkers as Predictors for Disability and Disease Progression in Multiple Sclerosis.

Authors:  Ana Paula Kallaur; Edna Maria Vissoci Reiche; Sayonara Rangel Oliveira; Andrea Name Colado Simão; Wildea Lice de Carvalho Jennings Pereira; Daniela Frizon Alfieri; Tamires Flauzino; Caio de Meleck Proença; Marcell Alysson Batisti Lozovoy; Damacio Ramón Kaimen-Maciel; Michael Maes
Journal:  Mol Neurobiol       Date:  2016-01-05       Impact factor: 5.590

7.  Control of immune-mediated disease of the central nervous system requires the use of a neuroactive agent: elucidation by the action of mitoxantrone.

Authors:  D Baker; J K O'Neill; A N Davison; J L Turk
Journal:  Clin Exp Immunol       Date:  1992-10       Impact factor: 4.330

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.